Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs

Journal of Managed Care Pharmacy

Volumn 12, Issue 8, 2006, Pages 656-664

  Raebel, Marsha A ^a,b   Carroll, Nikki M ^a   Simon, Steven R ^c   Andrade, Susan E ^d,e   Feldstein, Adrianne C ^f   Lafata, Jennifer Elston ^g   Nelson, Winnie W ^h   Chan, K Arnold ^i,j   Gunter, Margaret J ^k   Tolsma, Dennis ^l   Platt, Richard ^m,n  

^a CLINICAL RESEARCH UNIT   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HARVARD PILGRIM HEALTH CARE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f CENTER FOR HEALTH RESEARCH   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h XCENDA   (United States)

ⁱ i3 Magnifi Epidemiology ^*  (United States)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k LOVELACE CLINIC FOUNDATION   (United States)

^l KAISER PERMANENTE   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Aminotransferase; Amiodarone; Laboratory monitoring; Liver; Patient safety; Thyroid

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ENZYME INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBULATORY MONITORING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; EDUCATIONAL STATUS; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; LABORATORY TEST; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT SAFETY; THYROID FUNCTION; THYROID FUNCTION TEST; AMBULATORY CARE; COHORT ANALYSIS; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG EFFECT; INSURANCE; LIVER; MIDDLE AGED; MONITORING; RETROSPECTIVE STUDY; THYROID GLAND; UNITED STATES; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMIODARONE; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE CLAIM REPORTING; LABORATORY TECHNIQUES AND PROCEDURES; LIVER; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; RETROSPECTIVE STUDIES; THYROID GLAND; UNITED STATES;

EID: 33847336554     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.8.656     Document Type: Article

References (33)

1. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J. 2005;106:916-23.
2. Pollak PT. Oral amiodarone: historical overview and development. Pharmacother. 1998;18(6 pt 2):121S-126S.
3. Mechlis S, Lubin E, Laor J, et al. Amiodarone-induced thyroid gland dysfunction. Am J Cardiol. 1987;59:833-35.
4. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9:679-85.
5. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984;101:28-34.
6. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91:507-11.
7. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Monitoring amiodarone's toxicities: Recommendations, evidence, and clinical practice. Clin Pharmacol Ther. 2004;75:110-22.
8. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J. 1991;121:158-71.
9. Anonymous. Amiodarone (drug evaluation). Klasco RK. DRUGDEX System (electronic version); 2005. Greenwood Village, CO: Thomson Micromedex; 2005.
10. Pacerone tablets (Upsher-Smith). Physician's Desk Reference (electronic version); 2003. Greenwood Village, CO: Thomson Micromedex; 2003.
11. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.
12. Gittoes NJL, Franklyn JA. Drug-induced thyroid disorders. Drug Saf. 1995;13:46-55.
13. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther. 2004;75:342-51.
14. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol. 1997;20:608-18.
15. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B, for the Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Practical guidelines for clinicians who treat patients with amiodarone [special article]. Arch Intern Med. 2000;160:1741-48.
16. Cordarone (Wyeth Laboratories). Physician's Desk Reference. 54th ed. Montvale, NJ: Medical Economics Company, Inc.; 1999:3283-86.
17. Sanoski CA, Schoen MD, Gonzalez RC, Avitall B, Bauman JL. Rationale, development, and clinical outcomes of a multidisciplinary amiodarone clinic. Pharmacotherapy. 1998;18 (6 pt 2):146S-151S.
18. Hilleman D, Miller MA, Parker R, Doering P, Pieper JA. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy. 1998;18(6 pt 2):138S-145S.
19. Just VL, Williams RE. Improving the safety of amiodarone in the congestive heart failure population: baseline assessment of compliance with national guidelines in a large CHF clinic [abstract]. Value Health. 2002;5:126. Abstract HP3.
20. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons, Ltd.; 2005:261-69.
21. Chan KA, for the HMO Research Network CERTs Patient Safety Study Investigators. Development of a multipurpose dataset to evaluate potential medication errors in ambulatory settings. In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety: From Research to Implementation. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
22. McEvoy GK, ed. AHFS Drug Information (2004). Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2004.
23. Klasco RK. DRUGDEX System (electronic version); 2006. Greenwood Village, CO: Thomson Micromedex. Available at: http://www.thomsonhc.com. Accessed: October 12, 2005.
24. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-95.
25. Kreiger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R. Geocoding and monitoring US socioeconomic inequalities in mortality and cancer incidence: does choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol. 2002;156:471-82.
26. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30:791-98.
27. Bravo AER, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med. 2005;33:128-34.
28. Gilinsky NH, Briscoe GW, Kuo CS. Fatal amiodarone hepatotoxicity. Am J Gastroenterol. 1988;83:161-63.
29. Chang CC, Petrelli M, Tomashefski JF, et al. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug. A case report and review of the literature. Arch Pathol Lab Med. 1999;123:251-56.
30. Staubli M, Bircher J, Galeazzi RL, et al. Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol. 1983;24:485-94.
31. Hermida JS, Tcheng E, Jarry G, et al. Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace. 2004;6:169-74.
32. Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab. 2003;88:1999-2002.
33. Raebel MA, Chester EA, Newsom EE, et al. Randomized trial to improve laboratory safety monitoring of drug therapy in ambulatory patients. Pharmacotherapy. 2006;26:619-26.